In addition to helping treat various health and wellness conditions, new knowledge and research about minor cannabinoids, among the 100-200 that have been identified, is enabling cannabis businesses to sell a broader range of goods.
The products include less potent cannabinoids like CBN and THCV in addition to the standard THC and CBD products that are presently available on store shelves. The new goods, which include edibles and vapes, give cannabis businesses a chance to draw in customers looking for solutions to problems like obesity, insomnia, and nausea.
We should focus on figuring out which plants produce what effects and how to reliably offer those to customers rather than wasting time on meaningless strain titles.
Mike Hennesy, vice president of innovation at Colorado-based edibles manufacturer Wana Brands, said, “We’re better trying to understand which plants elicit what effects and how to consistently provide that to consumers so we can get away from all the meaningless strain names and get right to the point of how do you want this plant to help you feel.”
At the same time, scientists are examining the cannabis plant to see if minor cannabinoids can be useful in healing a variety of ailments, including epilepsy, traumatic brain injury, and other unidentified ailments. Four minor cannabinoids are used in the majority of the modern marijuana goods being created, but none of them have the same psychoactive properties as THC:
- Cannabigerol (CBG), which is said to reduce discomfort, nausea, and inflammation.
- One of the most prevalent cannabinoids in the plant, cannabichromene (CBC), was first identified in 1966 and is thought to have anti-cancer and anti-tumor properties.
- Cannabinol (CBN), a substance thought to be a sedative or slumber aid.
- Tetrahydrocannabivarin (THCV), also known as “diet weed,” is said to aid in weight reduction.
There is an increasing demand for these cannabinoids.
According to Grand View Research, the U.S. market for trace cannabis will be worth $4.9 billion in 2020. The market is anticipated to grow at a compound annual growth rate of 20.1% between 2021 and 2028, according to the San Francisco-based market research and consulting company.
The company highlights “the growing trend of using cannabinoid-based medicines instead of conventional ones, due to their positive health benefits for a wide range of health conditions, such as chronic pain, cancer, arthritis, neurological disorders, and metabolic disorders.”
Cannabis businesses provide fresh goods.
Products containing trace amounts of cannabinoids are being introduced by cannabis growers and makers in Canada and the US.
Day Trip is a new gummy that Cronos Group, an approved producer in Canada, introduced in December. It has a 3-1 CBC to THC ratio.
Two additional gummies manufactured with trace amounts of cannabinoids are available from the Toronto-based company: Deep Dreamz and Chill Bliss, both of which were introduced in October 2021. Cronos also offers three distinct vape products based on those varied gummy flavor combinations. Recently, Wana Brands introduced its Passionfruit Pineapple edible, which has a mix of 1:1:1 CBG:CBD:THC. The Stay Asleep gummy, which contains a combination of CBD, CBN, CBG, and THC along with 30 specialized terpenes, made its premiere in November of last year.
As a result, Hennesy said, “you’re getting a multitude of benefits with this formulation as opposed to just a THC product alone.”
And this is significant because each cannabinoid has a unique chemical structure and a unique affinity for various receptors. So, if I have THC and CBG, they each have a variety of cannabinoid receptor sites, some of which are convergent and others of which are not.
Better results than THC alone can result from combining these ingredients in the proper ratios.
